DOJ Begins Targeting COVID-19 Fraud Schemes
Client Alert | 1 min read | 03.20.20
In response to increased reporting of COVID-19-related fraud and misconduct, on March 16, 2020 Attorney General Barr directed all U.S. Attorneys to prioritize the prosecution of wrongdoers seeking to profit from this national crisis. Barr stated in his directive that "[t]he pandemic is dangerous enough without wrongdoers seeking to profit from public panic and this sort of conduct cannot be tolerated." Examples of such conduct include the sale of fake cures for COVID-19, phishing emails posing as the World Health Organization or the Centers for Disease Control and Prevention, and malware being inserted into mobile apps designed to track the spread of the virus.
U.S. Attorneys have already started responding to the directive. The U.S. Attorneys in the Western District of Pennsylvania and the Southern District of Mississippi have each appointed a dedicated COVID-19 fraud coordinator, while other U.S. Attorneys have launched hotlines and educational campaigns to combat COVID-19-related fraud. They are joined by other U.S. agencies that are starting to ring similar alarm bells, like the GSA which put out a notice this week that it has received reports of companies fraudulently claiming to be GSA vendors to mislead consumers into paying exorbitant prices for products associated with COVID-19. Over the coming days and weeks, we expect that U.S. Attorneys and agencies across the country will further shift their criminal and civil enforcement priorities to cases stemming from the COVID-19 crisis.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection

